The synaptotagmin family consists of seventeen membrane-associated regulators in mammals, each characterized by a short N-terminal transmembrane region and two cytoplasmic C2 domains that bind calcium with widely varying affinities. This heterogeneity is central to the review’s framework. Only a subset of isoforms functions as conventional fast calcium sensors; several others possess atypical or incomplete calcium-binding sites and appear to perform roles that do not depend on calcium triggering at all, such as membrane trafficking control, receptor turnover, and stress-response signaling. The authors organize the family by function, distinguishing rapid-release sensors such as SYT1, SYT2, and SYT9 in defined neuronal populations, activity-dependent and astrocytic secretion mediated by SYT4, asynchronous release and synaptic dynamics governed by SYT7, and a broader group including SYT3, SYT10, SYT11, SYT13, and SYT17 that connects membrane dynamics to trafficking, proteostasis, and neuronal resilience.

SYT1 remains the archetype. Embedded in synaptic vesicle membranes, it clamps the SNARE fusion machinery until an action potential delivers a pulse of calcium into the presynaptic terminal, at which point its C2 domains insert into membrane phospholipids and drive fast synchronous release. Human mutations in SYT1 produce a severe neurodevelopmental syndrome marked by intellectual disability, hypotonia, and epileptic activity, illustrating how a single point of failure in the fusion apparatus can derail brain development as a whole. The review also highlights emerging translational evidence around SYT1: proteins released from damaged synapses can be detected in cerebrospinal fluid, and SYT1 has been proposed as a candidate biomarker of synaptic injury. The authors are careful to frame this as promising but not yet clinically validated, a distinction that matters in a field where biomarker enthusiasm frequently outpaces reproducibility.

Where SYT1 mediates the lightning-fast synchronous component of neurotransmission, SYT2 and SYT9 handle fast release in specific neuronal populations, including circuits of the neuromuscular junction and specialized sensory pathways. Defects in these isoforms link directly to congenital myasthenic syndromes and neuromuscular junction disease, where the reliability of transmitter release determines whether muscle fibers receive adequate activation. SYT7, by contrast, shapes asynchronous release and vesicle recycling kinetics, fine-tuning the temporal structure of synaptic signaling and supporting forms of synaptic plasticity that depend on residual calcium. SYT4 occupies yet another niche, regulating activity-dependent secretion not only in neurons but also in astrocytes, thereby coupling neuronal activity to glial signaling and to the release of factors such as brain-derived neurotrophic factor that consolidate long-term synaptic change.

The review’s most distinctive contribution may be its treatment of the less glamorous isoforms. SYT3, located predominantly on the presynaptic plasma membrane rather than on vesicles, participates in activity-dependent bulk endocytosis and in the retrieval of synaptic vesicle components after intense stimulation. The authors describe preclinical intervention evidence suggesting that modulating SYT3-dependent endocytosis can protect synapses under metabolic stress, positioning the protein as a candidate therapeutic node. SYT13 likewise emerges from preclinical studies as a neuroprotective factor, with experimental manipulation of its expression influencing neuronal survival pathways, although the authors emphasize that such findings remain at the bench rather than the bedside.

SYT11 occupies a particularly compelling position at the intersection of membrane trafficking and protein quality control. The review identifies SYT11 as a Parkinson’s disease-related trafficking and proteostasis node, connecting vesicular transport, lysosomal function, and the cellular stress responses that determine whether damaged proteins are cleared or accumulate. Given that lysosomal dysfunction and protein aggregation are central themes in Parkinson’s pathology, a synaptotagmin isoform that participates in lysosomal exocytosis and autophagic flux offers a mechanistic bridge between two research literatures that have historically run in parallel. SYT10, expressed notably in the suprachiasmatic nucleus and involved in neurotrophin trafficking, and SYT17, associated with palmitoylation-dependent membrane association and stress signaling, round out a picture of a family whose roles extend deep into the glial and homeostatic dimensions of nervous system biology.

Human genetics, the authors acknowledge, provides comparatively limited direct evidence for some of these connections. The clearest clinical signal involves SYT14, where human genetic data link the isoform to an ataxic phenotype, consistent with its expression in Purkinje cells and its role in spinocerebellar neurodegeneration. For many other family members, the disease associations rest on animal models, cellular studies, and correlative human data rather than definitive Mendelian mutations. The review is notable for its evidence-stratified approach: the authors explicitly separate fast-release sensors with robust genetic and biophysical support, trafficking and proteostasis isoforms supported largely by preclinical work, and biomarker candidates whose clinical utility remains unproven. This candor about the strength of evidence is itself a contribution, offering a roadmap for where the field most urgently needs validation.

Unifying these strands is the concept of neuronal vulnerability. The authors propose a cellular and molecular framework in which synaptotagmin dysfunction destabilizes four interlocking processes: precise membrane fusion, vesicular trafficking and receptor turnover, proteostasis, and stress-response signaling. Because neurons are post-mitotic and metabolically demanding, they tolerate disruption of these processes poorly. Calcium-permeable AMPA receptor insertion, calmodulin-dependent signaling, and the balance between long-term potentiation and synaptic depression all depend on the regulated exo-endocytic cycle that synaptotagmins help orchestrate. When that cycle falters, excitotoxic signaling rises, receptor remodeling goes awry, and the neuron’s capacity to buffer stress erodes, linking a molecular defect in vesicle biology to the slow attrition of neural circuits observed in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis.

The translational implications are carefully hedged but genuinely intriguing. Beyond the SYT1 cerebrospinal fluid biomarker candidate and the preclinical interventions targeting SYT3 and SYT13, the review raises the possibility of adeno-associated virus-based gene approaches and small-molecule modulation of calcium-dependent membrane insertion as future therapeutic strategies, while stressing that none has reached clinical validation. The authors also note the relevance of synaptic vesicle glycoprotein 2A, a target of existing antiepileptic drugs and a widely used PET imaging marker of synaptic density, as a benchmark for how synaptic proteins can become clinically actionable. Whether synaptotagmins will follow that path depends on filling the gaps between biophysical mechanism, animal disease models, and human cohorts.

What emerges from this synthesis is a portrait of the synaptotagmin family as a systems-level regulator of nervous system health rather than a collection of interchangeable calcium sensors. From the millisecond choreography of vesicle fusion to the years-long trajectory of neurodegeneration, these proteins occupy decision points where membrane dynamics meet cellular survival. As the authors conclude, synaptotagmin dysfunction links membrane dynamics, synaptic instability, receptor remodeling, and stress-response failure into a coherent pathway toward neuronal vulnerability. For researchers hunting the molecular roots of neurological disease, that framework reframes an old question, how neurons communicate, into an urgently contemporary one: how the same machinery that transmits the mind can, when it breaks, break the neuron itself.

Subject of Research: Synaptotagmin family proteins and their roles in synaptic vesicle fusion and neurological disorders

Article Title: Synaptotagmin family proteins in neurological disorders: from synaptic vesicle fusion to neuronal vulnerability

Article References: Cui, J., He, J., Su, K., Luo, X., Wang, Z., Song, F., & Zhang, M. (2026). Synaptotagmin family proteins in neurological disorders: from synaptic vesicle fusion to neuronal vulnerability. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06446-0

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06446-0

Keywords: synaptotagmin, synaptic vesicle fusion, C2 domains, SNARE complex, neurodegeneration, SYT1, Parkinson's disease, lysosomal exocytosis, synaptic plasticity, neurodevelopmental disorder, family, proteins